A review of targeted therapies evaluated by the pediatric preclinical testing program for osteosarcoma.
about
Osteosarcoma: Cells-of-Origin, Cancer Stem Cells, and Targeted TherapiesPresent Advances and Future Perspectives of Molecular Targeted Therapy for OsteosarcomaMicroRNAs and Potential Targets in Osteosarcoma: ReviewAdvances in the management of osteosarcomaNew small molecules targeting apoptosis and cell viability in osteosarcomaVorinostat Enhances Cytotoxicity of SN-38 and Temozolomide in Ewing Sarcoma Cells and Activates STAT3/AKT/MAPK PathwaysAnimal models in osteosarcoma.Toward a drug development path that targets metastatic progression in osteosarcoma.mTORC1 maintains the tumorigenicity of SSEA-4(+) high-grade osteosarcoma.Histone Deacetylases in Bone Development and Skeletal Disorders.Identification of Synergistic, Clinically Achievable, Combination Therapies for OsteosarcomaZD6474, a new treatment strategy for human osteosarcoma, and its potential synergistic effect with celecoxibGenetically engineered pre-microRNA-34a prodrug suppresses orthotopic osteosarcoma xenograft tumor growth via the induction of apoptosis and cell cycle arrest.Osteosarcoma: mouse models, cell of origin and cancer stem cellIntegrating mechanisms of response and resistance against the tubulin binding agent Eribulin in preclinical models of osteosarcoma.Advances in therapy for pediatric sarcomas.Bone microenvironment signals in osteosarcoma development.LOX/COX inhibitors enhance the antineoplastic effects of all-trans retinoic acid in osteosarcoma cell lines.Expression levels of insulin receptor substrate-1 modulate the osteoblastic differentiation of mesenchymal stem cells and osteosarcoma cells.The formation of tight tumor clusters affects the efficacy of cell cycle inhibitors: a hybrid model study.Systematic Screening Identifies Dual PI3K and mTOR Inhibition as a Conserved Therapeutic Vulnerability in Osteosarcoma.Diagnostic assessment of osteosarcoma chemoresistance based on Virtual Clinical Trials.Differentially activated Src kinase in chemo-naïve human primary osteosarcoma cells and effects of a Src kinase inhibitor.Progress in the chemotherapeutic treatment of osteosarcoma
P2860
Q26745742-2F19FFE6-68EB-4920-AC53-699E3B5231C7Q26750631-278025C0-335C-48E4-B349-5F17AA7748F3Q26784033-FAA1A318-5C7E-4410-A2CA-96AC74E5566AQ28067644-A6406371-584E-4EC3-AB13-B2EF1E655830Q28547760-713F945A-0C37-42B1-B9D8-62B23C493C91Q28550980-626D5B76-717B-4B88-AAC5-FF0B7F442027Q33917772-41990EC4-3378-44F0-BD05-9C862FE7D771Q34052760-0A9F046A-3037-473C-86F4-07B4FE15BDE5Q35319234-A27CC983-E167-41E3-B843-1575D782BA5FQ36146330-6107B329-154F-4D82-B886-412750AA0FA4Q36316518-83513409-3E5B-4C85-9B3F-48D1180835F8Q36356334-5370EEFA-172A-46F1-BAE4-BD6675FBDDC5Q36928436-F6172E96-1489-411E-9E8F-24BF5EDDEC65Q37238378-DF3EA73B-230B-4B07-88A6-A937430EB46DQ37699295-F8E8BF50-3E71-4099-9E22-F681E11F4BCFQ38217354-6992FD78-3146-4D89-A847-5249ACB5F0A9Q38454980-BCAB30A5-6BED-4BB2-B0B3-454F3F06410DQ38998207-17EBA7C5-2352-4C0D-9E0F-96D87B1C1A71Q39033443-7D2557DE-396D-43C2-9D8E-5A74E9FC4A47Q41047795-46079243-3964-4208-ADE4-E8C8DA561F38Q41764229-D5AEECF9-BE6F-44CD-8322-77DBDD518C92Q42843612-7F09ACB4-8036-44BE-82F6-C428B3C798AEQ48274640-C8A5843A-0892-41BF-BAD0-1E3F945F3F34Q58572917-20CDCE4C-5870-4945-AD0E-98BB0C6B024C
P2860
A review of targeted therapies evaluated by the pediatric preclinical testing program for osteosarcoma.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
A review of targeted therapies ...... ting program for osteosarcoma.
@en
type
label
A review of targeted therapies ...... ting program for osteosarcoma.
@en
prefLabel
A review of targeted therapies ...... ting program for osteosarcoma.
@en
P2093
P2860
P356
P1476
A review of targeted therapies ...... sting program for osteosarcoma
@en
P2093
Davida Kamara
E Anders Kolb
Valerie B Sampson
P2860
P356
10.3389/FONC.2013.00132
P577
2013-05-31T00:00:00Z